Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Fasching

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 18, 2016
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implicationsStefan Stefanovic, Markus Wallwiener, Uros Karic, et al.
Oncoimmunology|January 3, 2024
Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancerLukas Heger, Gordon F Heidkamp, Lukas Amon, et al.
European Journal of Clinical Investigation|March 3, 2021
Mid-regional pro-atrial natriuretic peptide independently predicts short-term mortality in COVID-19Christoph C Kaufmann, Amro Ahmed, Mona Kassem, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 16, 2021
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptinChristoph C Kaufmann, Amro Ahmed, Mona Kassem, et al.
Wiener Klinische Wochenschrift|December 25, 2012
[Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2]Martin Clodi, H Eidemarie Abrahamian, Heinz Drexel, et al.
Diabetes, Obesity & Metabolism|November 29, 2022
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registryStephan Kress, Peter Bramlage, Reinhard W Holl, et al.
Journal of Clinical Medicine|February 11, 2023
Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19Christoph C Kaufmann, Amro Ahmed, Marie Muthspiel, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 3, 2016
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patientsBrigitte Rack, Julia Jückstock, Elisabeth Trapp, et al.
Cardiovascular Diabetology|October 24, 2020
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetesGuntram Schernthaner, Naim Shehadeh, Alexander S Ametov, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 18, 2016
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implicationsStefan Stefanovic, Markus Wallwiener, Uros Karic, et al.
Oncoimmunology|January 3, 2024
Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancerLukas Heger, Gordon F Heidkamp, Lukas Amon, et al.
European Journal of Clinical Investigation|March 3, 2021
Mid-regional pro-atrial natriuretic peptide independently predicts short-term mortality in COVID-19Christoph C Kaufmann, Amro Ahmed, Mona Kassem, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 16, 2021
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptinChristoph C Kaufmann, Amro Ahmed, Mona Kassem, et al.
Wiener Klinische Wochenschrift|December 25, 2012
[Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2]Martin Clodi, H Eidemarie Abrahamian, Heinz Drexel, et al.
Diabetes, Obesity & Metabolism|November 29, 2022
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registryStephan Kress, Peter Bramlage, Reinhard W Holl, et al.
Journal of Clinical Medicine|February 11, 2023
Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19Christoph C Kaufmann, Amro Ahmed, Marie Muthspiel, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 3, 2016
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patientsBrigitte Rack, Julia Jückstock, Elisabeth Trapp, et al.
Cardiovascular Diabetology|October 24, 2020
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetesGuntram Schernthaner, Naim Shehadeh, Alexander S Ametov, et al.
Pageof 12